MedPath

Gosuranemab

Generic Name
Gosuranemab
Drug Type
Biotech
CAS Number
1788032-39-2
Unique Ingredient Identifier
09FZ7Q0PQZ
Background

Gosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).

Clinical Trials
Related News

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

Phase 1
Terminated
Conditions
Primary Tauopathies
MAPT Mutation Carriers, Symptomatic
Traumatic Encephalopathy Syndrome
Corticobasal Degeneration Syndrome
Frontotemporal Lobar Degeneration With Tau Inclusions
Nonfluent Aphasia, Progressive
Interventions
Other: Placebo
First Posted Date
2018-09-05
Last Posted Date
2019-12-19
Lead Sponsor
University of California, San Francisco
Target Recruit Count
22
Registration Number
NCT03658135
Locations
🇺🇸

UCSF Memory and Aging Center, San Francisco, California, United States

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

Phase 2
Terminated
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2017-11-24
Last Posted Date
2022-11-08
Lead Sponsor
Biogen
Target Recruit Count
654
Registration Number
NCT03352557
Locations
🇺🇸

The Research Center of Southern California, Carlsbad, California, United States

🇸🇪

Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden

🇮🇹

Ospedale San Raffaele, Milano, Italy

and more 92 locations

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

Phase 2
Terminated
Conditions
Supranuclear Palsy, Progressive
Interventions
Drug: Placebo
First Posted Date
2017-03-01
Last Posted Date
2020-12-21
Lead Sponsor
Biogen
Target Recruit Count
490
Registration Number
NCT03068468
Locations
🇬🇧

Research Site, London, United Kingdom

🇺🇸

Research Name, Chicago, Illinois, United States

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Phase 1
Terminated
Conditions
Supranuclear Palsy, Progressive
Interventions
First Posted Date
2016-01-20
Last Posted Date
2020-05-18
Lead Sponsor
Biogen
Target Recruit Count
47
Registration Number
NCT02658916
Locations
🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 10 locations

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Phase 1
Completed
Conditions
Progressive Supranuclear Palsy
Interventions
Drug: Placebo
First Posted Date
2015-06-02
Last Posted Date
2018-09-04
Lead Sponsor
Biogen
Target Recruit Count
48
Registration Number
NCT02460094
Locations
🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

The University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of California, San Francisco, Medical Center at Parnassus, San Francisco, California, United States

and more 10 locations

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Phase 1
Completed
Conditions
Tauopathies
Interventions
First Posted Date
2014-11-19
Last Posted Date
2017-11-06
Lead Sponsor
Biogen
Target Recruit Count
65
Registration Number
NCT02294851
Locations
🇺🇸

WCCT Global, LLC, Cypress, California, United States

🇺🇸

Covance Clinical Research Unit Inc., Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy